Seven UK blood clot deaths after AstraZeneca vaccine

The UK medical regulator said Saturday (April 3) that out of 30 people who suffered blood clots after receiving the Oxford-AstraZeneca vaccine, seven have died.

The British acknowledgement of deaths comes as several European countries have paused the use of the AstraZeneca jab over a potential link to blood clots.

The UK’s Medicines and Healthcare products Regulatory Agency said in a statement that “out of the 30 reports up to and including 24 March, sadly seven have died”.

The Netherlands on Friday halted vaccinations with the AstraZeneca jab for people under the age of 60 after five new cases among women, one of whom died.

Germany took a similar decision earlier this week.

The European Medicines Agency (EMA), which like the World Health Organisation previously declared the AstraZeneca vaccine safe, is expected to announce updated advice on the issue on April 7.

The EMA said again on Wednesday it believes the vaccine is safe and that experts have found no specific risk factors such as age, gender or medical history.

The UK regulator said that the 30 reports of thrombosis, submitted by medics or members of the public via a government website, came after 18.1 million doses of the vaccine had been administered in the country.

Most of the cases (22) were cerebral venous sinus thrombosis, a rare condition when a blood clot forms in the brain.

Eight other cases saw people suffer thrombosis and low levels of blood platelets, which help blood clot.

There were no reports of blood clots from the Pfize-/BioNTech vaccine it said, adding that “our thorough review into these reports is ongoing.”

The regulator’s website says that on the basis of current data, the benefits of the vaccines against Covid-19 “continue to outweigh any risks”.

AstraZeneca said last month, following US efficiency trials, that its vaccine is 79 per cent effective at preventing the disease and does not increase the risk of blood clots.

The UK has administered more than 31 million first vaccine doses, using both the Oxford-AstraZeneca and the Pfizer-BioNTech jabs. People cannot choose which one they get.

The UK in June 2020 ordered 100 million doses of the Oxford-AstraZeneca vaccine and supported its development. It also ordered 30 million doses of the Pfizer-BioNTech vaccine the same year.